시장보고서
상품코드
2128965

크립토콕쿠스증 치료제 시장 : 유형별, 투여 경로별, 치료 영역별, 유통 채널별, 국가별, 지역별 - 업계 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)

Cryptococcosis Therapeutics Market, By Type, By Route of Administration, By Therapeutic Area, By Distribution Channel, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033

발행일: | 리서치사: 구분자 AnalystView Market Insights | 페이지 정보: 영문 349 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




가격
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.
US $ 3,250 금액 안내 화살표 ₩ 4,531,000
PDF (5 User License) help
PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 4,560 금액 안내 화살표 ₩ 6,358,000
PDF & Excel (Enterprise User License) help
PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 5,650 금액 안내 화살표 ₩ 7,877,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

크립토콕쿠스증 치료제 시장 규모는 2025년에 14억 7,080만 달러로 평가되었고, 2026-2033년 CAGR 6.1%로 성장할 전망입니다.

크립토콕쿠스증 치료제는 진균에 의해 유발되는 중증 전신 감염증의 치료에 도움이 됩니다. 치료 과정에는 강력한 항진균제의 정맥 내 투여와 더불어 두개내압을 관리하기 위한 신경학적 검사가 수행됩니다. 이 치료법은 주로 3단계로 구성됩니다. 이 치료법의 첫 번째 단계는 ‘도입 요법’으로, 암포테리신 B와 플루시토신이라는 두 가지 강력한 약물을 사용하여 병원체를 사멸시킵니다. 두 번째 단계는 ‘유지 요법’으로, 플루코나졸을 투여하여 병원체를 사멸시킵니다. 세 번째 단계는 재발을 억제함으로써 재발 위험을 낮추는 것입니다. 이러한 종합적인 치료 접근법을 통해 크립토코쿠스 감염증의 생존율이 향상되고 재발 위험이 감소합니다.

크립토콕쿠스증 치료제 시장 : 시장 역학

시장 확대를 뒷받침하는 진단 기술의 발전

MRI, CT, PET, 초음파, AI 기술을 활용한 영상 진단 등 최신 기술과 새로운 기법으로 인해 질환을 신속하고 정확하게 진단할 수 있게 됨에 따라, 진단 기술의 발전이 영상 진단 시장을 견인하고 있습니다. 예를 들어, 2026년 2월, 영국 정부 산하 의약품 및 헬스케어 제품 규제청(MHRA)은 영국 내 임상시험 건수가 17% 증가했다고 보고했습니다. 이는 2025년에 역대 어느 해보다 많은 신청이 승인되었음을 의미합니다. 또한, 지난 2년과 비교했을 때 1년 동안 신경기술 관련 연구(진단 및 뇌 연구 모두 포함) 건수가 증가했으며, 그 증가분은 전체 신청 건수의 25% 가까이를 차지하고 있습니다. 이러한 진보로 인해 진단 정확도가 향상되고 조기 발견이 가능해져, 보다 효과적인 환자 치료가 지원되고 있습니다.

크립토콕쿠스증 치료제 시장 : 시장 세분화 분석

세계 크립토콕쿠스증 치료제 시장은 유형, 투여 경로, 치료 영역, 유통 채널 및 지역을 기준으로 세분화됩니다.

유형별 부문에서는 항진균제가 이 질환의 1차 선택 치료제로서 그 유효성이 입증되었기 때문에 주요 시장 점유율을 차지하고 있습니다. 치료에 사용되는 약물로는 암포테리신 B, 플루시토신, 플루코나졸 등이 있습니다. 2025년 3월, 화이자(Pfizer)는 CRESEMBA®(이사부코나조늄 황산염)로 알려진 항진균제에 대해 호주에서 승인을 획득했습니다. 이 항진균제는 아졸 계열에 속하며, 침습성 아스페르길루스증 및 무코르증에 효과를 발휘합니다. 이들은 항진균제 부문의 확대에 기여할 것으로 예측됩니다.

치료 분야 부문에서 HIV/AIDS는 크립토콕쿠스증 치료제 시장에서 중요한 위치를 차지하고 있으며, 이는 진행된 HIV/AIDS 환자에서 크립토콕쿠스증의 높은 유병률과 이 환자 집단에서 항진균 치료에 대한 큰 수요에 의해 주도되고 있습니다. 예를 들어, 2026년 8월 델리주 에이즈 대책 협회(정부)에 따르면, NACO HIV는 델리주 15-49세 연령층의 HIV 유병률이 0.32%이며, 주 내 HIV 감염자 수는 약 5만 8,563명에 달한다고 보고했습니다. 델리 주에서는 추정에 따르면 연간 약 2,961건의 신규 HIV 감염과 연간 약 1,121명의 HIV 관련 사망이 발생하는 것으로 알려져 있습니다. 이는 해당 지역에서 HIV/에이즈의 부담이 지속적으로 증가하고 있음을 보여줍니다. 이러한 HIV/에이즈 부담 증가에 따라, 환자들 사이에서 효과적인 크립토콕쿠스증 치료제에 대한 수요가 높아질 것으로 예측됩니다.

크립토콕쿠스증 치료제 시장 : 지역별 분석

북미에는 크립토콕쿠스증 치료법 개발에 적극적으로 나서고 있는 주요 기업과 연구 기관이 거점을 두고 있습니다. 공중보건 기관과 제약 기업 사이에는 여러 합작 사업이 존재합니다. 예를 들어, 2026년 1월 기준 세계보건기구(WHO)에 따르면 150개국 이상이 WHO가 발행한 모델 목록을 활용하여 자국의 필수 의약품 목록을 수립하고 있으며, 이는 150개국 이상이 WHO 모델 목록에 기반하여 작성된 ‘국가 필수 의약품 목록’을 채택하고 있음을 의미합니다. ‘WHO 필수 의약품 모델 목록 2025’에는 520종 이상의 의약품이 포함되어 있으며, 그중 374종은 소아용 의약품입니다. 이러한 노력은 치료법 개발을 촉진하고 의약품 접근성을 개선하는 동시에, 북미 전역의 크립토콕쿠스증 관리 체계를 향상시키는 데 기여하고 있습니다.

목차

제1장 크립토콕쿠스증 치료제 시장 개요

제2장 주요 요약

제3장 크립토콕쿠스증 치료제 주요 시장 동향

제4장 크립토콕쿠스증 치료제 산업 분석

제5장 크립토콕쿠스증 치료제 시장 : 높아지는 지정학적 긴장의 영향

제6장 크립토콕쿠스증 치료제 시장 구도

제7장 크립토콕쿠스증 치료제 시장 : 유형별

제8장 크립토콕쿠스증 치료제 시장 : 투여 경로별

제9장 크립토콕쿠스증 치료제 시장 : 치료 영역별

제10장 크립토콕쿠스증 치료제 시장 : 유통 채널별

제11장 크립토콕쿠스증 치료제 시장 : 지역별

제12장 주요 벤더 분석 : 크립토콕쿠스증 치료제 산업

제13장 AnalystView 전방위 전망

AJY 26.09.17

Cryptococcosis Therapeutics Market size was valued at US$ 1,470.8 Million in 2025, expanding at a CAGR of 6.1% from 2026 to 2033.

Cryptococcosis therapeutics help in the treatment of a serious systemic infection that is brought about by the fungi with the aid of potent antifungal agents intravenously and neurological testing in order to manage intracranial pressure. This method is comprised of three main steps. The first step of the method involves induction, in which the use of two powerful drugs, amphotericin B and flucytosine, is employed in an attempt to kill the organisms. The second phase includes the consolidation phase, which involves the administration of fluconazole to kill the organism. The third phase involves reducing the risk of recurrence through the reduction of relapse. This comprehensive treatment approach improves survival outcomes and reduces recurrence risks in cryptococcal infections.

Cryptococcosis Therapeutics Market- Market Dynamics

Advancements In Diagnostic Techniques To Boost Market Expansion

Advancements in diagnostic techniques are driving the diagnostic imaging market, as newer technologies and new techniques such as MRI, CT, PET, ultrasound, and imaging using AI technology provide for rapid and accurate diagnosis of diseases. For example, in February 2026, the Medicines and Healthcare Products Regulatory Agency (MHRA), per the UK government, reported a 17% growth in the number of clinical investigation trials in the UK, which means that more applications have been approved in 2025 than in any other year before. Moreover, there has been a rise in the number of neurotechnology investigations (both diagnostics and brain research) in a year compared to the past two years; the increment has accounted for nearly 25% of their total applications. These advancements are improving diagnostic accuracy, enabling earlier detection, and supporting more effective patient care.

Cryptococcosis Therapeutics Market- Segmentation Analysis:

The Global Cryptococcosis Therapeutics Market is segmented on the basis of Type, Route of Administration, Therapeutic Area, Distribution Channel, and Region.

Among the given types, antifungal agents hold a major share under the type segment because of their proven use as the first-line treatment for the disease. The drugs used in the treatment include amphotericin B, flucytosine, and fluconazole. In March 2025, Pfizer Inc. was granted Australian approval of its antifungal agent known as CRESEMBA(R) (isavuconazonium sulfate). This antifungal belongs to the azole family that acts against invasive aspergillosis and mucormycosis. These will help in increasing the antifungal agents segment.

HIV/AIDS holds the key position in the Cryptococcosis Therapeutics Market under the Therapeutic Area segment, driven by the high incidence of cryptococcal disease among people with advanced HIV/AIDS and the significant need for antifungal treatment in this population. For instance, in August 2026, according to the Delhi State AIDS Control Society (Gov.), NACO HIV reported that Delhi had an HIV prevalence of 0.32% among the aged 15-49 years, which amounted to approximately 58,563 people living with HIV in the state. In Delhi the estimations suggested around 2,961 new HIV infections per year and approximately 1,121 deaths due to HIV per year. It shows that the burden of HIV/AIDS is continually increasing in the region. This rising HIV/AIDS burden is expected to increase demand for effective cryptococcosis therapeutics among affected patients.

Cryptococcosis Therapeutics Market- Geographical Insights

North America is home to leading pharmaceutical companies and research institutions that actively participate in creating treatments for cryptococcosis. There are some joint ventures between the public health institutions and the pharmaceutical firms. For example, in January 2026, according to the World Health Organization (WHO), more than 150 nations have adopted their national lists of essential medicines using the model list issued by the WHO, meaning that more than 150 countries use the National List of Essential Medicines developed based on the WHO Model List. The WHO Model List of Essential Medicines 2025 includes more than 520 medicines, of which 374 are children's medicines. These initiatives strengthen treatment development, improve access, and support better cryptococcosis management across North America.

Cryptococcosis Therapeutics Market- Competitive Landscape:

The Cryptococcosis Therapeutics market is also working towards making acquisitions, particularly in the drug categories and geographies. The leading companies operating in this market are Astellas Pharma Inc., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals, Merck & Co., Inc., and Pfizer Inc., and these companies are looking towards increasing the efficacy of treatment of the disease that causes cryptococcosis. In November 2025, Merck & Co., Inc. entered into a partnership with Cidara Therapeutics for strengthening its antifungal product portfolio through CD421, which is an echinocandin in development for the treatment of serious fungal infections. These strategic initiatives are expected to strengthen antifungal treatment options and support continued market growth.

Recent Developments:

In February 2026, the investigational oral amphotericin B drug MAT2203 from Matinas BioPharma was featured in a published clinical case report for its successful treatment of cryptococcal meningitis, proving its worth as an oral drug for the treatment of cryptococcosis.

In September 2025, Basilea Pharmaceutica AG received an additional USD 25 million grant funding from the Biomedical Advanced Research and Development Authority (BARDA) for the development of its novel antifungal agents fosmanogepix and BAL2062 for treating tough-to-treat cases of fungal infection, including cryptococcosis.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CRYPTOCOCCOSIS THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Asahi Kasei Pharma Corporation
  • Sun Pharmaceutical Industries Limited
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited
  • Basilea Pharmaceutica AG
  • F2G Limited
  • Matinas BioPharma Holdings Inc.
  • Lupin Limited
  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Amplyx Pharmaceuticals, Inc.
  • Flynn Pharma Ltd.
  • NuCare Pharmaceuticals, Inc.
  • Sanofi
  • Abbott Laboratories
  • Others

GLOBAL CRYPTOCOCCOSIS THERAPEUTICS MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033

  • Combination Therapy
  • Immunotherapy
  • Antifungal Agents

GLOBAL CRYPTOCOCCOSIS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

  • Intravenous
  • Topical
  • Oral

GLOBAL CRYPTOCOCCOSIS THERAPEUTICS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2020 - 2033

  • Transplantation
  • Immunocompromised Patients
  • HIV/AIDS

GLOBAL CRYPTOCOCCOSIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033

  • Pharmacies
  • Online Pharmacies
  • Hospitals

GLOBAL CRYPTOCOCCOSIS THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Cryptococcosis Therapeutics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
  • 2.2. Competitive Insights

3. Cryptococcosis Therapeutics Key Market Trends

  • 3.1. Cryptococcosis Therapeutics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Cryptococcosis Therapeutics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Cryptococcosis Therapeutics Market Opportunities
  • 3.4. Cryptococcosis Therapeutics Market Future Trends

4. Cryptococcosis Therapeutics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Cryptococcosis Therapeutics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Cryptococcosis Therapeutics Market Landscape

  • 6.1. Cryptococcosis Therapeutics Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Cryptococcosis Therapeutics Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2025 & 2033 (%)
    • 7.1.2. Combination Therapy
    • 7.1.3. Immunotherapy
    • 7.1.4. Antifungal Agents

8. Cryptococcosis Therapeutics Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
    • 8.1.2. Intravenous
    • 8.1.3. Topical
    • 8.1.4. Oral

9. Cryptococcosis Therapeutics Market - By Therapeutic Area

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Therapeutic Area, 2025 & 2033 (%)
    • 9.1.2. Transplantation
    • 9.1.3. Immunocompromised Patients
    • 9.1.4. HIV/AIDS

10. Cryptococcosis Therapeutics Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
    • 10.1.2. Pharmacies
    • 10.1.3. Online Pharmacies
    • 10.1.4. Hospitals

11. Cryptococcosis Therapeutics Market - By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Cryptococcosis Therapeutics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Cryptococcosis Therapeutics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.17. Denmark
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.17.3. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.17.4. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.17.5. Denmark Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.17.6. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.18. Rest of Europe
      • 11.3.18.1. Overview
      • 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.3.18.3. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.3.18.5. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.3.18.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Cryptococcosis Therapeutics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.16. Taiwan
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.16.3. Taiwan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.16.4. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.16.5. Taiwan Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.16.6. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.17. Vietnam
      • 11.4.17.1. Overview
      • 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.17.3. Vietnam Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.17.4. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.17.5. Vietnam Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.17.6. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.18. Rest of APAC
      • 11.4.18.1. Overview
      • 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.4.18.3. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.4.18.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.4.18.5. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.4.18.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Cryptococcosis Therapeutics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Cryptococcosis Therapeutics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.14. Iran
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.14.3. Iran Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.14.4. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.14.5. Iran Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.14.6. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.15. Qatar
      • 11.6.15.1. Overview
      • 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.15.3. Qatar Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.15.4. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.15.5. Qatar Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.15.6. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.16. Rest of MEA
      • 11.6.16.1. Overview
      • 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
      • 11.6.16.3. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
      • 11.6.16.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
      • 11.6.16.5. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2020 - 2033 (US$ Million)
      • 11.6.16.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Cryptococcosis Therapeutics Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Gilead Sciences, Inc.
    • 12.2.2. Merck & Co., Inc.
    • 12.2.3. Asahi Kasei Pharma Corporation
    • 12.2.4. Sun Pharmaceutical Industries Limited
    • 12.2.5. Dr. Reddy's Laboratories Ltd.
    • 12.2.6. Cipla Limited
    • 12.2.7. Basilea Pharmaceutica AG
    • 12.2.8. F2G Limited
    • 12.2.9. Matinas BioPharma Holdings Inc.
    • 12.2.10. Lupin Limited
    • 12.2.11. Bausch Health Companies Inc.
    • 12.2.12. Teva Pharmaceutical Industries Ltd.
    • 12.2.13. Viatris Inc.
    • 12.2.14. Amplyx Pharmaceuticals, Inc.
    • 12.2.15. Flynn Pharma Ltd.
    • 12.2.16. NuCare Pharmaceuticals, Inc.
    • 12.2.17. Sanofi
    • 12.2.18. Abbott Laboratories
    • 12.2.19. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기